Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Science 37 backs 2022 revenue view $86M-$96M, consensus $91.13M » 06:05
05/09/22
05/09
06:05
05/09/22
06:05
SNCE

Science 37

$3.55 /

-0.18 (-4.83%)

Sees 2022 adjusted EBITDA…

Sees 2022 adjusted EBITDA ($65M)-($69M).

ShowHide Related Items >><<
SNCE Science 37
$3.55 /

-0.18 (-4.83%)

SNCE Science 37
$3.55 /

-0.18 (-4.83%)

11/16/21 Lake Street
Science 37 price target raised to $20 from $15 at Lake Street
11/01/21 Lake Street
Lake Street starts Science 37 at Buy, says digitized trials 'here to stay'
11/01/21 Lake Street
Science 37 initiated with a Buy at Lake Street
11/01/21 William Blair
Blair starts Science 37 at buy with efficient trial push 'here to stay'
SNCE Science 37
$3.55 /

-0.18 (-4.83%)

SNCE Science 37
$3.55 /

-0.18 (-4.83%)

Earnings
Science 37 reports Q1 EPS 35c, consensus (22c) » 06:04
05/09/22
05/09
06:04
05/09/22
06:04
SNCE

Science 37

$3.55 /

-0.18 (-4.83%)

Reports Q1 revenue…

Reports Q1 revenue $18.7M, consensus $15.06M. Q1 net income included a non-cash gain of $75.5M resulting from revaluation of the earn-out liability. Net bookings were $30.6M in Q1 vs. $40.7M for the same period in 2021. Net bookings for the quarter ended March 31, 2022 were negatively impacted by two large COVID study cancellations. "The first quarter of 2022 was marked by continued execution across all of our strategic priorities. We started the year with strong demand for our differentiated, end to end platform and revenue growth of 50% year over year. Additionally, we remained laser-focused on driving more cost out of the business," said CEO David Coman. "With our sales pipeline at an all-time high, several imminent new product introductions and rigid cost management, we anticipate that our current cash position is sufficient to support our plans to achieve long-term profitability."

ShowHide Related Items >><<
SNCE Science 37
$3.55 /

-0.18 (-4.83%)

SNCE Science 37
$3.55 /

-0.18 (-4.83%)

11/16/21 Lake Street
Science 37 price target raised to $20 from $15 at Lake Street
11/01/21 Lake Street
Lake Street starts Science 37 at Buy, says digitized trials 'here to stay'
11/01/21 Lake Street
Science 37 initiated with a Buy at Lake Street
11/01/21 William Blair
Blair starts Science 37 at buy with efficient trial push 'here to stay'
SNCE Science 37
$3.55 /

-0.18 (-4.83%)

SNCE Science 37
$3.55 /

-0.18 (-4.83%)

Over a month ago
Hot Stocks
Science 37 appoints Shaalan Beg to Global Management Team » 07:57
03/31/22
03/31
07:57
03/31/22
07:57
SNCE

Science 37

$5.60 /

-0.2 (-3.45%)

Science 37 Holdings …

Science 37 Holdings nnounced it is adding Shaalan Beg, M.D., M.S.C.S. to its Global Management Team. Dr. Beg comes to Science 37 from the University of Texas, Southwestern Medical Center in Dallas, Texas where he served as Medical Director for the Clinical Research Office at the Simmons Comprehensive Cancer and held the position of Director Gastrointestinal Medical Oncology and Associate Professor of Hematology and Medical Oncology.

ShowHide Related Items >><<
SNCE Science 37
$5.60 /

-0.2 (-3.45%)

SNCE Science 37
$5.60 /

-0.2 (-3.45%)

11/16/21 Lake Street
Science 37 price target raised to $20 from $15 at Lake Street
11/01/21 Lake Street
Lake Street starts Science 37 at Buy, says digitized trials 'here to stay'
11/01/21 Lake Street
Science 37 initiated with a Buy at Lake Street
11/01/21 William Blair
Blair starts Science 37 at buy with efficient trial push 'here to stay'
SNCE Science 37
$5.60 /

-0.2 (-3.45%)

SNCE Science 37
$5.60 /

-0.2 (-3.45%)

On The Fly
Fly Intel: Pre-market Movers » 08:54
03/22/22
03/22
08:54
03/22/22
08:54
BABA

Alibaba

$103.59 /

-4.67 (-4.31%)

, JILL

J.Jill

$15.45 /

-0.39 (-2.46%)

, GDS

GDS Holdings

$37.04 /

-0.365 (-0.98%)

, RAIL

FreightCar America

$4.35 /

+0.26 (+6.36%)

, NKE

Nike

$130.10 /

-1.11 (-0.85%)

, SCPH

scPharmaceuticals

$5.12 /

-0.08 (-1.54%)

, EVAX

Evaxion Biotech

$3.25 /

+0.29 (+9.80%)

, DAVE

Dave

$10.45 /

+0.43 (+4.29%)

, OKTA

Okta

$169.40 /

-5.13 (-2.94%)

, SNCE

Science 37

$5.92 /

+0.04 (+0.68%)

Check out this morning's…

ShowHide Related Items >><<
SNCE Science 37
$5.92 /

+0.04 (+0.68%)

SCPH scPharmaceuticals
$5.12 /

-0.08 (-1.54%)

RAIL FreightCar America
$4.35 /

+0.26 (+6.36%)

OKTA Okta
$169.40 /

-5.13 (-2.94%)

NKE Nike
$130.10 /

-1.11 (-0.85%)

JILL J.Jill
$15.45 /

-0.39 (-2.46%)

GDS GDS Holdings
$37.04 /

-0.365 (-0.98%)

EVAX Evaxion Biotech
$3.25 /

+0.29 (+9.80%)

DAVE Dave
$10.45 /

+0.43 (+4.29%)

BABA Alibaba
$103.59 /

-4.67 (-4.31%)

BABA Alibaba
$103.59 /

-4.67 (-4.31%)

03/16/22 US Tiger
China Internet sector upgraded to Outperform from Neutral at US Tiger
03/14/22 JPMorgan
JPMorgan double downgrades Alibaba to sell as global investors exit
03/14/22 JPMorgan
Alibaba downgraded to Underweight from Overweight at JPMorgan
03/11/22 UBS
Weibo downgraded to Neutral at UBS on weaker ad growth and margin outlook
JILL J.Jill
$15.45 /

-0.39 (-2.46%)

GDS GDS Holdings
$37.04 /

-0.365 (-0.98%)

02/09/22 Morgan Stanley
Morgan Stanley upgrades GDS Holdings to Overweight, sees bottom being in
02/09/22 Morgan Stanley
GDS Holdings upgraded to Overweight from Equal Weight at Morgan Stanley
02/08/22 Truist
GDS Holdings price target lowered to $85 from $115 at Truist
01/31/22 RBC Capital
GDS Holdings price target lowered to $65 from $80 at RBC Capital
RAIL FreightCar America
$4.35 /

+0.26 (+6.36%)

06/11/21 OTR Global
Railcar maker view improved to Positive from Mixed at OTR Global
NKE Nike
$130.10 /

-1.11 (-0.85%)

03/22/22 Truist
Nike price target raised to $176 from $164 at Truist
03/22/22 Morgan Stanley
Nike Q3 beat 'high-quality,' re-rating will take some time, says Morgan Stanley
03/22/22 BMO Capital
Nike price target lowered to $150 from $170 at BMO Capital
03/22/22 Deutsche Bank
Nike price target raised to $175 from $173 at Deutsche Bank
SCPH scPharmaceuticals
$5.12 /

-0.08 (-1.54%)

09/09/21 SVB Leerink
SVB Leerink starts scPharmaceuticals with a Market Perform, $6 target
09/09/21 SVB Leerink
scPharmaceuticals initiated with a Market Perform at SVB Leerink
EVAX Evaxion Biotech
$3.25 /

+0.29 (+9.80%)

08/19/21 Ladenburg
Evaxion transferred with Buy rating, $18 target at Ladenburg
07/30/21
Fly Intel: Top five analyst initiations
07/30/21 Lake Street
Evaxion Biotech initiated with a Buy at Lake Street
DAVE Dave
$10.45 /

+0.43 (+4.29%)

OKTA Okta
$169.40 /

-5.13 (-2.94%)

03/21/22 Stifel
Okta price target lowered to $195 from $200 at Stifel
03/08/22 Mizuho
Okta upgraded to Buy from Neutral at Mizuho
03/04/22 Guggenheim
Okta price target lowered to $240 from $265 at Guggenheim
03/03/22 BMO Capital
Okta price target lowered to $215 from $270 at BMO Capital
SNCE Science 37
$5.92 /

+0.04 (+0.68%)

11/16/21 Lake Street
Science 37 price target raised to $20 from $15 at Lake Street
11/01/21 Lake Street
Lake Street starts Science 37 at Buy, says digitized trials 'here to stay'
11/01/21 Lake Street
Science 37 initiated with a Buy at Lake Street
11/01/21 William Blair
Blair starts Science 37 at buy with efficient trial push 'here to stay'
SNCE Science 37
$5.92 /

+0.04 (+0.68%)

SCPH scPharmaceuticals
$5.12 /

-0.08 (-1.54%)

RAIL FreightCar America
$4.35 /

+0.26 (+6.36%)

OKTA Okta
$169.40 /

-5.13 (-2.94%)

NKE Nike
$130.10 /

-1.11 (-0.85%)

JILL J.Jill
$15.45 /

-0.39 (-2.46%)

GDS GDS Holdings
$37.04 /

-0.365 (-0.98%)

EVAX Evaxion Biotech
$3.25 /

+0.29 (+9.80%)

DAVE Dave
$10.45 /

+0.43 (+4.29%)

BABA Alibaba
$103.59 /

-4.67 (-4.31%)

  • 05
    Nov
OKTA Okta
$169.40 /

-5.13 (-2.94%)

NKE Nike
$130.10 /

-1.11 (-0.85%)

BABA Alibaba
$103.59 /

-4.67 (-4.31%)

RAIL FreightCar America
$4.35 /

+0.26 (+6.36%)

OKTA Okta
$169.40 /

-5.13 (-2.94%)

NKE Nike
$130.10 /

-1.11 (-0.85%)

BABA Alibaba
$103.59 /

-4.67 (-4.31%)

OKTA Okta
$169.40 /

-5.13 (-2.94%)

NKE Nike
$130.10 /

-1.11 (-0.85%)

GDS GDS Holdings
$37.04 /

-0.365 (-0.98%)

EVAX Evaxion Biotech
$3.25 /

+0.29 (+9.80%)

DAVE Dave
$10.45 /

+0.43 (+4.29%)

BABA Alibaba
$103.59 /

-4.67 (-4.31%)

Earnings
Science 37 sees CY21 revenue $86M-$92M, consensus $104.22M » 07:04
03/22/22
03/22
07:04
03/22/22
07:04
SNCE

Science 37

$5.92 /

+0.04 (+0.68%)

Science 37 is providing…

Science 37 is providing guidance for the calendar year ending December 31, 2022 for total revenues between $86 and $96 million.

ShowHide Related Items >><<
SNCE Science 37
$5.92 /

+0.04 (+0.68%)

SNCE Science 37
$5.92 /

+0.04 (+0.68%)

11/16/21 Lake Street
Science 37 price target raised to $20 from $15 at Lake Street
11/01/21 Lake Street
Lake Street starts Science 37 at Buy, says digitized trials 'here to stay'
11/01/21 Lake Street
Science 37 initiated with a Buy at Lake Street
11/01/21 William Blair
Blair starts Science 37 at buy with efficient trial push 'here to stay'
SNCE Science 37
$5.92 /

+0.04 (+0.68%)

Earnings
Science 37 reports Q4 EPS (60c), consensus (21c) » 07:04
03/22/22
03/22
07:04
03/22/22
07:04
SNCE

Science 37

$5.92 /

+0.04 (+0.68%)

Reports Q4 revenue…

Reports Q4 revenue $20.4M, consensus $14.78M. "Our impressive financial performance in the fourth quarter and for the full year 2021 reflects our team's continued strong execution and commitment to expanding patient access and reach of our agile clinical trial offerings," said David Coman, Chief Executive Officer of Science 37. "As we look ahead to 2022, we expect a sustained market shift toward more decentralization and strong demand for our differentiated Operating System. We are on a clear pathway to growth and long-term profitability as we redefine the future of clinical research; and we are confident that we are well positioned to deliver on our objectives."

ShowHide Related Items >><<
SNCE Science 37
$5.92 /

+0.04 (+0.68%)

SNCE Science 37
$5.92 /

+0.04 (+0.68%)

11/16/21 Lake Street
Science 37 price target raised to $20 from $15 at Lake Street
11/01/21 Lake Street
Lake Street starts Science 37 at Buy, says digitized trials 'here to stay'
11/01/21 Lake Street
Science 37 initiated with a Buy at Lake Street
11/01/21 William Blair
Blair starts Science 37 at buy with efficient trial push 'here to stay'
SNCE Science 37
$5.92 /

+0.04 (+0.68%)

Hot Stocks
Science 37 publishes CNS therapeutic data from CNS survey » 07:58
03/01/22
03/01
07:58
03/01/22
07:58
SNCE

Science 37

$8.00 /

+0.07 (+0.88%)

Science 37 Holdings …

Science 37 Holdings published new CNS therapeutic data validating the growing trend toward decentralization as two-thirds of CNS survey respondents plan to execute an agile or decentralized clinical trial in 2022, an increase of more than 35 percent from last year. According to analysis, the CNS Research & Development spend will reach $32 billion USD by 2026, resulting in more than 4,000 clinical trials. To uncover these new trends in CNS clinical trials methodologies, Science 37 conducted a study of more than 70 clinical research executives, between December 2021 and January 2022. For CNS studies, survey respondents cited unexpected delays, data quality and limited patient populations among the key challenges for clinical trials, with effective patient recruitment as the single biggest challenge by more than 100% comparatively to the second challenge of endpoint collection. Being able to eliminate geographic barriers with agile and decentralized approaches and helping to ease patient burden can help alleviate these concerns and enable more efficient centralized enrollment into studies. The new data and insights also paint a vivid picture of the clinical trials landscape for the year ahead for CNS studies, suggesting significant increases in agile and decentralized approaches across numerous conditions-including major depressive disorder, Alzheimer's disease, and Parkinson's disease-and executed with a myriad of permutations of patient communities, mobile nursing, telemedicine investigators and connected devices - further demonstrating the need for a centralized Operating System with unified technology and centralized networks to effectively execute. Among the findings: Less than 60 percent of CNS respondents are planning to execute a traditional, site-based clinical trial in 2022, down from three in four for the previous year. Unexpected delays, data quality, and limited patient populations all ranked highly among the issues keeping respondents up at night, regarding CNS trials in general. Respondents cited the greatest single challenge of running an effective CNS study was patient recruitment by more than 100% comparatively to the second challenge of endpoint collection. Electronic clinical outcomes assessment and electronic patient-reported outcomes were cited as the most prevalent decentralized components in CNS, with two-thirds of CNS respondents planning to use these tools - showing the rising embrace of digital data collection and evidence generation. Among the largest-growing decentralized components of CNS studies cited were mobile nurses, up 40 percent and up 38 percent, respondents cited usage of Metasites or virtual sites that can enable more universal geographic coverage and access for patients. The three greatest perceived benefits of including agile and decentralized components in CNS clinical trials were increased patient retention, increased patient diversity and faster patient recruitment.

ShowHide Related Items >><<
SNCE Science 37
$8.00 /

+0.07 (+0.88%)

SNCE Science 37
$8.00 /

+0.07 (+0.88%)

11/16/21 Lake Street
Science 37 price target raised to $20 from $15 at Lake Street
11/01/21 Lake Street
Lake Street starts Science 37 at Buy, says digitized trials 'here to stay'
11/01/21 Lake Street
Science 37 initiated with a Buy at Lake Street
11/01/21 William Blair
Blair starts Science 37 at buy with efficient trial push 'here to stay'
SNCE Science 37
$8.00 /

+0.07 (+0.88%)

Hot Stocks
Science 37's Operating System receives ISO certification » 08:15
02/24/22
02/24
08:15
02/24/22
08:15
SNCE

Science 37

$7.71 /

+0.25 (+3.35%)

Science 37 Holdings, the…

Science 37 Holdings, the Agile Clinical Trial Operating System announced its Operating System has earned ISO 27001 certification for cybersecurity management as well as the ISO 27701:2019 privacy management certification extension. These two certifications demonstrate Science 37's continued commitment to embrace quality, robust cybersecurity, privacy and data protection rights.

ShowHide Related Items >><<
SNCE Science 37
$7.71 /

+0.25 (+3.35%)

SNCE Science 37
$7.71 /

+0.25 (+3.35%)

11/16/21 Lake Street
Science 37 price target raised to $20 from $15 at Lake Street
11/01/21 Lake Street
Lake Street starts Science 37 at Buy, says digitized trials 'here to stay'
11/01/21 Lake Street
Science 37 initiated with a Buy at Lake Street
11/01/21 William Blair
Blair starts Science 37 at buy with efficient trial push 'here to stay'
SNCE Science 37
$7.71 /

+0.25 (+3.35%)

Over a quarter ago
Hot Stocks
Science 37 says provider network grows sixfold in 2021 » 07:56
02/17/22
02/17
07:56
02/17/22
07:56
SNCE

Science 37

$8.30 /

-0.09 (-1.07%)

Science 37 Holdings…

Science 37 Holdings bolstered its centralized network of community providers by six times during the past year, contracting with more than 800 healthcare organizations and gaining access to nearly 28 million patients worldwide. Currently, less than three percent of physicians participate as clinical trial investigators, primarily due to infrastructure burdens that often serve as a deterrent - preventing more than 97 percent of providers from contributing to research. By expanding its network of community providers, Science 37 enables physicians-providers to present clinical research as a care option to their patients, without having to add expensive clinical research infrastructure.

ShowHide Related Items >><<
SNCE Science 37
$8.30 /

-0.09 (-1.07%)

SNCE Science 37
$8.30 /

-0.09 (-1.07%)

11/16/21 Lake Street
Science 37 price target raised to $20 from $15 at Lake Street
11/01/21 Lake Street
Lake Street starts Science 37 at Buy, says digitized trials 'here to stay'
11/01/21 Lake Street
Science 37 initiated with a Buy at Lake Street
11/01/21 William Blair
Blair starts Science 37 at buy with efficient trial push 'here to stay'
SNCE Science 37
$8.30 /

-0.09 (-1.07%)

Hot Stocks
Science 37, physIQ collaborate to enhance trial data from connected devices » 07:57
02/03/22
02/03
07:57
02/03/22
07:57
SNCE

Science 37

$7.89 /

+0.06 (+0.77%)

Science 37 Holdings…

Science 37 Holdings announced a collaboration to help research sponsors use remote biosensors and machine learning to build more robust data sets. This will help increase the number of digital biomarkers and generate insights from continuous data streams to more quickly and objectively demonstrate the safety and efficacy of treatments. physIQ's robust platform scalability, near real-time capabilities, established FDA clearance, and proven ability to support large global clinical trials strengthen Science 37's ability to support additional novel digital biomarkers, advance clinical events detection and provide more proactive safety monitoring. physIQ enables Sponsors to efficiently identify valuable digital measures from large amount of noise inherent in biosensors.

ShowHide Related Items >><<
SNCE Science 37
$7.89 /

+0.06 (+0.77%)

SNCE Science 37
$7.89 /

+0.06 (+0.77%)

11/16/21 Lake Street
Science 37 price target raised to $20 from $15 at Lake Street
11/01/21 Lake Street
Lake Street starts Science 37 at Buy, says digitized trials 'here to stay'
11/01/21 Lake Street
Science 37 initiated with a Buy at Lake Street
11/01/21 William Blair
Blair starts Science 37 at buy with efficient trial push 'here to stay'
SNCE Science 37
$7.89 /

+0.06 (+0.77%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.